Безпосередні результати реконструкції аортального клапана за методикою Озакі

Б.М. Тодуров, І.Ю. Мокрик, І.О. Аксьонова, Н.В. Понич, Х.М. Монастирська, О.В. Єпанчінцева, І.М. Кузьмич, В.Б. Демянчук

Література 

1. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur J Cardio-Thoracic Surgery. 2017;52:616-664.
2. Hamid MS, Sabbah HS, Stein PD. Finite element evaluation of stresses on closed leaflets of bioprosthetic heart valves with flexible stentes. Finite Elements in Analysis and Design. 1985;1(3):213-225.
3. Otto CM, Lind BK, Gersh BJ, Siscovick DS. Association of aortic valve sclerosis with cardiovascular mortality and morbidity in elderly. New Engl J Med. 1999;341:142-147.
4. Ozaki S, Kawase I, Yamashita H. et al. A total of 404 cases of aortic valve reconstruction with glutaraldehyde-treated autologous pericardium. J Thorac Cardiovasc Surg. 2014;147:301-306.
5. Ross J, Braunwald E. Aortic stenosis. Circulation. 1968;38(Suppl. 5):61-67.

Досвід впровадження операцій зі штучним кровообігом на базі відділення судинної хірургії обласної лікарні

Ю.С. Спірін

Література  

1.Konopleva LF, Kushnir SL. Tumors of the heart. Possibilities of clinical diagnosis. UMJ Heart and Vessels (Ukrainian). 2013;2:23-26. (in Ukr.).

2.Kundin VYu, Satyr MV, Noverko IV, Khokhlov AV. The possibilities of lung perfusion scintigraphy in the diagnosis of pulmonary embolism and chronic thromboembolic pulmonary hypertension. Cardiac Surgery and Interventional Cardiology. 2017;2:33-39. (in Ukr.).

3.Rudenko YV, Bezrodnyi AB. Guidelines of the European Society of Cardiology on the prevention, diagnosis and treatment of infective endocarditis.  UMJ Heart and Vessels (Ukrainian). 2011;1:20-34. (in Russ.).

4.Rudenko YV, Stremenyuk 0T, Kovalyova IS. Guidelines of the European Society of Cardiology 2013 on the management of stable coronary artery disease. UMJ Heart and Vessels (Ukrainian). 2014;1:8-18. (in Russ.).

5.Acker M.A, Parides M.K, Perrault L.P. et al. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. New Engl J Med. 2014;370:23-32.

6.Baldus S, Schillinger W, Franzen O. et al. MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail. 2012;14:1050-1055.

7.Windecker S, Kolh P, Alfonso F. et al. 2014 ESC/EACTS Guidelines on Myocardial Revascularization of the European Society of Cardiology (ESC) and The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2014;35:2541-2619. 

1

Ехокардіографічні предиктори рецидиву ішемічної мітральної недостатності після анулопластики мітрального клапана

Н.Д. Орищин, Ю.А. Іванів

Література 

1. Kovalenko VM, Sychov OS, Ivaniv YA, Dolzhenko MM et al. Quantitative echocardiographic evaluation of the cavities of the heart. Recommendations of the Working Group on Functional Diagnostics of the Association of Cardiologists of Ukraine and the Association of Specialists in Heart Arrhythmology and Electrophysiology. Кyiv, 2013. (in Ukr.).
2. Baumgartner H, Falk V, Bax J. et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;38:2739-2786.
3. Bouma W, van der Horst IC, Wijdh-den Hamer IJ. et al. Chronic ischaemic mitral regurgitation. Current treatment results and new mechanism-based surgical approaches. Eur J Cardiothorac Surg. 2010;37:170-185.
4. Bursi F, Enriquez-Sarano M. et al. Heart failure and death after myocardial infarction in the community: the emerging role of mitral regurgitation. Circulation. 2005;111:295-301. 
5. Calafiore AM, Di Mauro M, Varone E. Echocardiographically based tratment of chronic ischemic mitral regurgitation. J Thorac Cardiovasc Surg. 2011;141 (5):1150-1156.
6. Deja MA, Grayburn PA, Sun B. et al. Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. Circulation. 2012;125:2639-2648. 
7. Enriquez-Sarano M, Miller FJ, Hayes S. et al. Effective mitral regurgitant orifice area: clinical use and pitfalls of the proximal isovelocity surface area method. J Am Coll Cardiol. 1995;25:703-709. 
8. Fattouch K, Lancellotti P, Castrovinci S. et al. Papillary muscle relocation in conjunction with valve annuloplasty improve repair results in severe ischemic mitral regurgitation. J Thorac Cardiovasc Surg. 2012;143:1352-1355.
9. Garsse L, Gelsomino S, Luca F. et al. Importance of anterior leaflet tethering in predicting recurrence of ischemic mitral regurgitation after restrictive annuloplasty. Thorac Cardiovаsc Surg. 2012;143:S54-59.
10. Gelsomino S, Garasse LV, Lucà F. et al. Impact of preoperative anterior leaflet tethering on the recurrence of ischemic mitral regurgitation and the lack of left ventricular reverse remodeling after restrictive annuloplasty. J Am Soc Echocardiogr. 2011;24:1365-1375.
11. Goldstein D, Moskowitz AJ, Gelijns AC. Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. New Engl J Med. 2016;374(4):344-353. 
12. Grigioni F, Enriquez-Sarano M, Zehr KJ. et al. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation. 2001;103:1759-1764. 
13. Hung J, Papakostas L, Tahta SA. et al. Mechanism of recurrent ischemic mitral regurgitation after annuloplasty: continued LV remodeling as a moving target. Circulation. 2004;110 (Suppl. II):II-85–II-90. 
14. Kim K, Kaji S, An Y, Nishino TT. et al. Interpapillary muscle distance independently affects severity of functional mitral regurgitation in patients with systolic left ventricular dysfunction. J. Thorac. Cardiovasc. Surg. 2014;148:434-440.
15. Komeda M, Koyama Y, Fukaya S. et al. Papillary heads “optimization” in repairing functional mitral regurgitation. J Thorac Cardiovasc Surg. 2012;144:1262-1264.
16. Lamas GA, Mitchell GF, Flaker GC. et al. Clinical significance of mitral regurgitation after acute myocardial infarction. Survival and Ventricular Enlargement Investigators. Circulation. 1997;96:827-833. 
17. Lancellotti P, Tribouilloy C, Hagendorff A, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J. – Cardiovascular Imaging. 2013;14:611-644. 
18. Lang RM, Bierig M, Devereux RB. et al, Members of the Chamber Quantification Writing Group. Recommendations for Chamber Quantification: a Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463. 
19. Lee L, Kwon MH, Cevasco M. et al. Рostoperative recurrence of mitral regurgitation after annuloplasty for functional mitral regurgitation. Ann Thorac Surg. 2012;94:1211-1217. 
20. Magne J, Pibarot P, Dumesnil JG. Continued global left ventricular remodeling is not the sole mechanism responsible for the late recurrence of ischemic mitral regurgitation after restrictive annuloplasty. J Am Soc Echocardiogr. 2009;22:1256-1264.
21. Menicanti L, Di Donato M, Frigiola A. et al. Ischemic mitral regurgitation: intraventricular papillary muscle imbrication without mitral ring during left ventricular restoration. J Thorac Cardiovasc Surg. 2002;123:1041-1050.
22. Morris J, Gardner M. Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and ratio and rates. Brit Med J. 1988;296:1313-1316.
23. Onorati F, Rubino AS, Marturano D. et al. Midterm clinical and echocardiographic results and predictors of mitral regurgitation recurrence following restrictive annuloplasty for ischemic cardiomyopathy. J Thorac Cardiovasc Surg. 2009;138:654-662.
24. Shiota M, Gillinov AM, Takasaki K. et al. Recurrent mitral regurgitation late after annuloplasty for ischemic mitral regurgitation. Echocardiography. 2011;28:161-166.
25. Szymanski C, Levine RA, Tribouilloy C, Zheng H, Handschumacher MD, Tawakol A, Hung J. Impact of mitral regurgitation on exercise capacity and clinical outcomes in patients with ischemic left ventricular dysfunction. Am J Cardiol. 2011;108:1714-1720
26. Yiu SF, Enriquez-Sarano M, Tribouilloy C, Seward JB, Tajik AJ. Determinants of the degree of functional mitral regurgitation in patients with systolic left ventricular dysfunction: a quantitative clinical study. Circulation. 2000;102:1400-1406. 
27. Ueno T, Sakata R, Iguro Y. et al. Preoperative advanced left ventricular remodeling predisposes to recurrence of ischemic mitral regurgitation with less reverse remodeling. J. Heart Valve Dis. 2008;17:36-41.

Зміни якості життя та критерії ефективності аортокоронарного шунтування в пацієнтів зі стабільною ішемічною хворобою серця і збереженою фракцією викиду лівого шлуночка

Ю.А. Борхаленко, О.Й. Жарінов, К.О. Міхалєв, О.А. Єпанчінцева, Б.М. Тодуров

Література 

1. Buziashvili YI, Sigaev IY, Khananashvili EM. et al. Evaluation of left ventricular diastolic function in patients with ischemic heart disease before and after coronary artery bypass surgery. The Russian Journal of Thoracic and Cardiovascular Surgery. 2001;4:30-35. (in Russ.).
2. Kovalenko VM, Lutay MІ, Sirenko YM. Cardiovascular disease. Classification, standards of diagnosis and treatment: Methodical recommendations of the Association of Cardiologists of Ukraine. Кyiv, 2010. (in Ukr.).
3. Lutai MI, Lysenko AF Medicinal treatment of stable angina pectoris. Methodical recommendations of the Working Group on Atherosclerosis and Chronic Chondritis of the Association of Cardiologists of Ukraine. Кyiv, 2013. (in Ukr.).
4. ATS Statement: Guidelines for the six – minute walk test. Amer J Respir Crit Care Med. 2002;166:111-117.
5. Bengtson A, Karlsson T, Herlitz J. On the waiting list for possible coronary revascularisation. Symptoms relief during the first year and association between quality of life and the very long-term mortality risk. Int J Cardiol. 2008;123(3):271-276.
6. Caine N, Harrison SCW, Sharples LD, Wallwork J. Prospective study of quality of life before and after coronary artery bypass grafting. BMJ. 1991;302:511-516.
7. Chocron S, Etievent JP, Viel JF. et al. Prospective study of quality of life before and after open heart operations. Ann Thorac Surg. 1996;61:153-157.
8. Endicott KM, Amdur RL, Greenberg MD, Trachiotis GD. B-type Natriuretic peptide predicts morbidity and long-term mortality in coronary artery bypass grafting and valve surgery. Innovations (Phila). 2016;11(6):439-443.
9. Falcoz PE, Chocron S, Laluc F. et al. Gender analysis after elective open heart surgery: a two-year comparative study of quality of life. Ann Thorac Surg. 2006;81:1637-1643.
10. Fox Amanda A, Marcantonio Edward R, Collard Charles D. et al. Elevated Peak Postoperative B-type Natriuretic Peptide Predicts Decreased Longer-Term Physical Function after Primary Coronary Artery Bypass Graft Surgery. Anesthesiology. 2011;114(4):807-816.
11. Hak T, Willems D, van der Wal G. et al. A qualitative validation of the Minnesota Living with Heart Failure Questionnaire. Qual Life Res. 2004;13:417-426.
12. Herlitz J, Haglid M, Wiklund I. et al. Improvement in quality of life during 5 years after coronary artery bypass grafting. Coron Artery Dis. 1998;9(8):519-526.
13. Holm J, Vidlund M, Vanky F. et al. EuroSCORE II and N-terminal pro-B-type natriuretic peptide for risk evaluation: an observational longitudinal study in patients undergoing coronary artery bypass graft surgery. Br J Anaesth. 2014;113(1):75-82.
14. Hunt JO, Hendrata MV, Myles PS. Quality of life 12 months after coronary artery bypass graft surgery. Heart Lung. 2000;29:401-411.
15. Kattainen E, Sintonen H, Kettunen R, Merilainen P. Health-related quality of life of coronary artery bypass grafting and percutaneous transluminal coronary artery angioplasty patients: 1-year follow-up. Int J Technol Assess Health Care. 2005;21:172-179.
16. Le Grande MR, Elliott PC, Murphy BM. et al. Health related quality of life trajectories and predictors following coronary artery bypass surgery. Health Qual Life Outcomes. 2006;4:49.
17. Loponen P, Luther M, Korpilahti K. et al. HRQOL after coronary artery bypass grafting and percutaneous coronary intervention for stable angina. Scand Cardiovasc J. 2009;43(2):94-99.
18. Loponen P, Luther M, Korpilahti K. et al. Quality of life during 18 months after coronary artery bypass grafting. Eur J Cardiothor Surgery. 2007;(32):77-82.
19. Montalescot G, Sechtem U, Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949-3003.
20. Murad Junior Jamil Alli, Nakazone Marcelo Arruda, Machado Mauricio de Nassau, de Godoy Moacir Fernandes. Predictors of mortality in cardiac surgery: brain natriuretic peptide type B. Braz. J Cardiovasc Surg. 2015;30(2):182-187.
21. Nagueh SF, Appleton CP, Gillebert TC. et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009;10:1525-2167.
22. Peric Vladan M, Borzanovic Milorad D, Stolic Radojica V. et al. Severity of angina as a predictor of quality of life changes six months after coronary artery bypass surgery. Ann Thorac Surg. 2006;81:2115-2120.
23. Peric Vladan M, Borzanovic M, Stolic R. et al. Predictors of worsening of patients’ quality of life six months after coronary artery bypass surgery. J Card Surg. 2008;23:648-654.
24. Peric Vladan M, Stolic Radojica V, Jovanovic Aleksandar N. et al. Severity of angina as a predictor of quality of life changes six months after coronary artery bypass surgery. Ann Thorac Surg. 2006;81:2115-2120.
25. Ross AC, Ostrow L. Subjectively perceived quality of life after coronary artery bypass surgery. Am J Crit Care. 2001;10(1):11-16.
26. Rumsfeld JS, Magid DJ, Plomondon ME. et al. Health-related quality of life after percutaneous coronary intervention versus coronary bypass surgery in high-risk patients with medically refractory ischemia. J Am Coll Cardiol. 2003;41(10):1732-1738.
27. Seok-Jae H, Vojtech M, Barry A. Implications of coronary artery disease in heart failure with preserved ejection fraction (Mayo clinic). J Amer Coll Cardiology. 2014;63:2817-2827.
28. Sharma R, Anker SD. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Eur. Heart J. 2002;23:886-891.
29. Spertus JA, Winder JA, Dewhurst TA. et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995;25(2):333-341.
30. Spertus JA, Winder JA, Dewhurst TA. et al. Monitoring the quality of life in patients with coronary artery disease. Amer J Heart. 1994;74:1240-1244.
31. Terou I, Shigenori M, Terumi H. et al. Left Ventricular diastolic dysfunction in coronary artery disease: effects of coronary revascularization. Clin Cardiol. 1992;15:577-581.
32. Yamamoto K, Redfield MM, Nishimura RA. Analysis of left ventricular diastolic function. Heart. 1996;75(2):27-35.
33. Yancy CW, Jessup M, Bozkurt B. et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240-e327.
34. Yun KL, Sintek CF, Fletcher AD. et al. Time related quality of life after elective cardiac operation. Ann Thorac Surg. 1999;68(4):1314-1320.
35. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): Conceptual framework and item selection. Medical Care. 1992;30:473-483.
36. Windecker S, Kolh P, Alfonso F. et al. 2014 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2014;35:2541-2619.

Клінічний підхід до оцінювання переносності та процедур десенситизації ацетилсаліцилової кислоти в пацієнтів з ішемічною хворобою серця та гіперчутливістю до нестероїдних протизапальних препаратів

G. Cortellini, A. Romano, A. Santucci та інші

Література 

1. Negi S, Anand A. Atherosclerotic coronary heart disease-epidemiology, classification and management. Cardiovasc Hematol Disord Drug Targets. 2010;10:257-261.
2. Kasper L, Sladek K, Duplaga M, Bochenek G, Liebhart J, Gladysz U et al. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy. 2003;58:1064-1066.
3. Dona I, Blanca-Lopez N, Torres MJ, Garcіa-Campos J, Garcіa-Nunez I, Gomez F et al. Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients. J Investig Allergol Clin Immunol. 2012;22:363-371.
4. Pang S, Shi SY, Zhang YJ, Iqbal J, Chen XY, Ren XM et al. The impact of dual antiplatelet therapy duration on primary composite endpoint after drug-eluting stent implantation: a meta-analysis of 10 randomized trials. Int J Cardiol. 2016;202:504- 506.
5. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376:1233-1243.
6. Schaefer OP, Gore JM. Aspirin sensitivity: the role for aspirin challenge and desensitization in postmyocardial infarction patients. Cardiology. 1999;91:8-13.
7. Feng CH, White AA, Stevenson DD. Characterization of aspirin allergies in patients with coronary artery disease. Ann Allergy Asthma Immunol. 2013;110:92-95.
8. Mueller C, Patrono C, Valgimigli M, Collet JP, Roffi M. Questions and answers on diagnosis and risk assessment: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2015; pii: ehv409 (Epub ahead of print).
9. Ramanuja S, Breall JA, Kalaria VG. Approach to «aspirin allergy» in cardiovascular patients. Circulation. 2004;110:1-4.
10. Gollapudi RR, Teirstein PS, Stevenson DD, Simon RA. Aspirin sensitivity: implications for patients with coronary artery disease. JAMA. 2004;292:3017-3023.
11. Pattanaik D, Lieberman P, Das P. Aspirin sensitivity and coronary artery disease: implications for the practicing cardiologist. Future Cardiol. 2012;8:555-562.
12. White AA, Stevenson DD, Woessner KM, Simon RA. Approach to patients with aspirin hypersensitivity and acute cardiovascular emergencies. Allergy Asthma Proc. 2013;34:138-142.
13. Latib A, Ielasi A, Ferri L, Chieffo A, Godino C, Carlino M et al. Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: a proposed alternative regimen. Int J Cardiol. 2013;165:444-447.
14. McMullan KL. Aspirin allergy in patients with myocardial infarction: the allergist’s role. Ann Allergy Asthma Immunol. 2014;112:90-93.
15. Wong JT, Nagy CS, Krinzman SJ, Maclean JA, Bloch KJ. Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema. J Allergy Clin Immunol. 2000;105:997-1001.
16. Silberman S, Neukirch-Stoop C, Steg PG. Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol. 2005;95:509-510.
17. Alijotas-Reig J, San Miguel-Moncіn M, Cistero-Bahіma A. Aspirin desensitization in the treatment of antiphospholipid syndrome during pregnancy in ASA-sensitive patients. Am J Reprod Immunol. 2006;55:45-50.
18. Hobbs L, Lyle B. Rapid oral aspirin desensitization for patients with aspirin allergy requiring dual antiplatelet therapy. Conn Med. 2008;72:87-89.
19. Rossini R, Angiolillo DJ, Musumeci G, Scuri P, Invernizzi P, Bass TA et al. Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation. Am J Cardiol. 2008;101:786-789.
20. Dalmau G, Gaig P, Gazquez V, Merce J. Rapid desensitization to acetylsalicylic acid in acute coronary syndrome patients with NSAID intolerance. Rev Esp Cardiol. 2009;62:224-225.
21. Ortega-Loayza AG, Raza S, Minisi AJ, Topaz O, Heller A, Jovin IS. Aspirin desensitization/challenge in 3 patients with unstable angina. Am J Med Sci. 2010;340:418-420.
22. Christou A, Kafkas N, Marinakos A, Katsanos S, Papanikitas K, Patsilinakos S. Rapid desensitisation of patients with aspirin allergy who undergo coronary angioplasty. Hellenic J Cardiol. 2011;52:307–310.
23. Cortellini G, Testi S, Severino M, Chechi T, Iorno ML, Santucci A et al. Aspirin challenge/desensitisation before coronary stenting in subjects with history of hypersensitivity. A pragmatic approach. Eur Ann Allergy Clin Immunol. 2012;44:160-162.
24. De Luca G, Verdoia M, Binda G, Schaffer A, Suryapranata H, Marino P. Aspirin desensitization in patients undergoing planned or urgent coronary stent implantation. A single-center experience. Int J Cardiol. 2013;167:561-563.
25. Lee JK, Tsui KL, Cheung CY, Chau CH, Chan HL, Wu KL et al. Aspirin desensitisation for Chinese patients with coronary artery disease. Hong Kong Med J. 2013;19:207-213.
26. McMullan KL, Wedner HJ. Safety of aspirin desensitization in patients with reported aspirin allergy and cardiovascular disease. Clin Cardiol. 2013;36:25-30.
27. Cordoba-Soriano JG, Corbі-Pascual M, Lopez-Neyra I, Navarro-Cuartero J, Hidalgo-Olivares V, Barrionuevo-Sanchez MI et al. Early aspirin desensitization in unstable patients with acute coronary syndrome: short and long-term efficacy and safety. Eur Heart J Acute Cardiovasc Care. 2016; 5:41-50.
28. Kowalski ML, Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Bochenek G et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013;68:1219-1232.
29. Quiralte J, Blanco C, Castillo R, Delgado J, Carrillo T. Intolerance to nonsteroidal antiinflammatory drugs: results of controlled drug challenges in 98 patients. J Allergy Clin Immunol. 1996;98:678-685.
30. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczynska M, Picado C, Scadding G et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy. 2007;62:1111-1118.
31. Dona I, Blanca-Lopez N, Cornejo-Garіca A, Torres MJ, Laguna JJ, Fernandez J et al. Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clin Exp Allergy. 2011;41:86-95.
32. Viola M, Rumi G, Valluzzi RL, Gaeta F, Caruso C, Romano A. Assessing potential determinants of positive provocation tests in subjects with NSAID hypersensitivity. Clin Exp Allergy. 2011;41:96-103.
33. Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Cortellini G, Nizankowska-Mogilnicka E et al. Clinical management of patients with a history of urticaria/angioedema induced by multiple NSAIDs: an expert panel review. Int Arch Allergy Immunol. 2013;160:126-133.
34. Blanca-Lopez N, J Torres M, Dona I, Campo P, Rondon C, Seoane Reula ME et al. Value of the clinical history in the diagnosis of urticaria/angioedema induced by NSAIDs with cross-intolerance. Clin Exp Allergy. 2013;43:85-91.
35. Cernadas JR, Brockow K, Romano A, Aberer W, Torres MJ, Bircher A et al. General considerations on rapid desensitization for drug hypersensitivity – a consensus statement. Allergy. 2010;65:1357-1366.
36. Blanca M, Perez E, Garcia JJ, Miranda A, Terrados S, Vega JM et al. Angioedema and IgE antibodies to aspirin: a case report. Ann Allergy. 1989;62:295-298.
37. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553-1559.
38. Heestermans T, van’t Hof AW, ten Berg JM, van Werkum JW, Boersma E, Mosterd A et al. The golden hour of prehospital reperfusion with triple antiplatelet therapy: a sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy. Am Heart J. 2010;160:1079-1084.
39. EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 1994;330:956-961.
40. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
41. CAPTURE investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet. 1997;349:1429-1435.
42. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
43. De Luca G, Ucci G, Cassetti E, Marino P. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. J Am Coll Cardiol. 2009;53:1668–1673.
44. Moliterno DJ, TENACITY Steering Committee and Investigators. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. Catheter Cardiovasc Interv. 2011;77:1001-1009.
45. Balghith MA. High bolus tirofiban vs abciximab in acute STEMI patients undergoing primary PCI – the Tamip study. Heart Views. 2012;13:85-90.
46. Szczeklik A, Sanak M. The broken balance in aspirin hypersensitivity. Eur J Pharmacol. 2006;533:145-155.
47. Mastalerz L, Setkowicz M, Sanak M, Szczeklik A. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol. 2004;113:771-775.
48. Macy E, Bernstein JA, Castells MC, Gawchik SM, Lee TH, Settipane RA et al. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol. 2007;98:172-174.

Особливості ураження правого шлуночка серця злоякісною пухлиною

 Р.М. Вітовський, В.В. Ісаєнко, В.Ф. Онищенко, О.А. Піщурін, Д.М. Дядюн, І.І. Жеков

Література 

1. Knyshov GV, Vitovsky RM, Zakharova VP. Heart tumors. Кyiv, 2005. 256 p. (in Russ.).
2. Barnes H, Conaglen P, Russell P. et al. Clinicopathological and surgical experience with primary cardiac tumors. Asian. Cardiovasc. Thorac. Ann. 2014;22:1054-1058.
3. Barreiro M, Renilla A, Jimenez JM. et al. Primary cardiac tumors: 32 years of experience from a Spanish tertiary surgical center. Cardiovasc. Pathol. 2013;22:424-427.
4. Bruce CJ. Cardiac tumours: diagnosis and management. Heart. 2011;97(2):151-160.
5. Burazor I, Aviel-Ronen S, Imazio M. et al. Primary malignancies of the heart and pericardium. Clin. Cardiol. 2014;37:582-588.
6. Cresti A, Chiavarelli M, Glauber M. et al. Incidence rate of primary cardiac tumors: a 14-year population study. J. Cardiovasc. Med. (Hagerstown). 2016;17:37-43.
7. Dias RR, Fernandes F, Ramires FJ. et al. Mortality and embolic potential of cardiac tumors. Arq. Bras. Cardiol. 2014;103:13-18.
8. Habertheuer A, Laufer G, Wiedemann D. et al. Primary cardiac tumors on the verge of oblivion: a European experience over 15 years. J. Cardiothorac. Surg. 2015;10:56.
9. Isogai T, Yasunaga H, Matsui H. et al. Factors affecting in-hospital mortality and likelihood of undergoing surgical resection in patients with primary cardiac tumors. J. Cardiol. 2016;10:1016.
10. Padalino MA, Vida VL, Boccuzzo G. et al. Surgery for primary cardiac tumors in children: early and late results in a multicenter European Congenital Heart Surgeons Association study. Circulation. 2012;126:22-30.

Сучасні ехокардіографічні підходи до діагностики легеневої гіпертензії та неінвазивного визначення тиску в легеневій артерії

 М.Ю. Колесник

Література 

1. Abbas AE, Fortuin FD, Schiller NB. et al. A simple method for noninvasive estimation of pulmonary vascular resistance. J Am Coll Cardiol. 2003;41(6):1021-1027.
2. Chemla D, Castelain V, Humbert M. et al. New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. Chest. 2004;126(4):1313-1317.
3. Currie PJ, Seward JB, Chan KL. et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol. 1985;6(4):750-756.
4. D'Alto M, Romeo E, Argiento P. et al. A simple echocardiographic score for the diagnosis of pulmonary vascular disease in heart failure. J Cardiovascular Medicine. 2017;18(4):237-243. doi: 10.2459/JCM.0000000000000485.
5. Er F, Ederer S, Nia AM. et al. Accuracy of doppler-echocardiographic mean pulmonary artery pressure for diagnosis of pulmonary hypertension. PLoS ONE. 2010;5(12):1-7.
6. Fisher MR, Forfia PR, Chamera E. et al. Accuracy of doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179(7):615-621.
7. Galiè N, Humbert M, Vachiery JL. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. doi: 10.1093/eurheartj/ehv317.
8. Greiner S, Jud A, Aurich M. et al. Reliability of noninvasive assessment of systolic pulmonary artery pressure by doppler echocardiography compared to right heart catheterization: analysis in a large patient population. J Am Heart Assoc. 2014;3(4):1-8.
9. Gupta NK, Agrawal RK, Srivastav AB, Ved ML. Echocardiographic evaluation of heart in chronic obstructive pulmonary disease patient and its correlation with the severity of disease. Lung India. 2011;28(2):105-109.
10. Hachulla E, Clerson P, Airò P. et al. Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. Rheumatology. 2015. 54(7):1262-1269. doi: 10.1093/rheumatology/keu450.
11. Huttin O, Voilliot D, Mandry D. et al. All you need to know about the tricuspid valve: Tricuspid valve imaging and tricuspid regurgitation analysis. Arch Cardiovasc Dis. 2016;109(1):67-80.
12. Janda S, Shahidi N, Gin K, Swiston J. Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis. Heart. 2011;97(8):612-622.
13. Kitabatake A, Inoue M, Asao M. et al. Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique. Circulation. 1983;68(2):302-309.
14. Lam CS, Borlaug BA, Kane GC. et al. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation. 2009;119(20):2663-2670.
15. Lam CS, Roger VL, Rodeheffer RJ. et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J. Am. Coll. Cardiol. 2009;53(13):1119-1126.
16. Masuyama T, Kodama K, Kitabatake A. et al. Continuous-wave Doppler echocardiographic detection of pulmonary regurgitation and its application to noninvasive estimation of pulmonary artery pressure. Circulation. 1986;74(3):484-492.
17. McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation. 2001;104:2797-2802.
18. Parasuraman S, Walker S, Loudon BL. et al. Assessment of pulmonary artery pressure by echocardiography – A comprehensive review. Int. J. Cardiol. Heart Vasc. 2016;12:45-51.
19. Park JS, Ahn J, Choi JH. et al. The predictive value of echocardiography for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism in Korea. Korean. J. Intern. Med. 2017;32(1):85-94.
20. Sade LE, Gulmez O, Eroglu S. et al. Non-invasive estimation of right ventricular filling pressure by ratio of early tricuspid inflow to annular diastolic velocity in patients with and without recent cardiac surgery. J. Am. Soc. Echocardiogr. 2007;20:982-988.
21. Simonneau G, Gatzoulis MA, Adatia I. et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2013;62:34-41.
22. Singh JP, Evans JC, Levy D. et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am. J. Cardiol. 1999;83(6):897-902.
23. Syyed R, Reeves JT, Welsh D. et al. The relationship between the components of pulmonary artery pressure remains constant under all conditions in both health and disease. Chest. 2008;133:633-639.
24. Van Riel AC, Opotowsky AR, Santos M. et al. Accuracy of echocardiography to estimate pulmonary artery pressures with exercise: a simultaneous invasive-noninvasive comparison. Circ. Cardiovasc. Imaging. 2017;10(4):1-16. doi: 10.1161/CIRCIMAGING.116.005711.
25. Yang B, DeBenedictus C, Watt T. et al. The impact of concomitant pulmonary hypertension on early and late outcomes following surgery for mitral stenosis. J. Thorac. Cardiovasc. Surg. 2016;152(2):394-400.